Interventional radiology

Stent Grafts Market 2020-2024 | Increasing Prevalence Of Aortic Aneurysms And Co-morbidities to Boost Growth | Technavio

Friday, May 29, 2020 - 6:45pm

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • View the full release here: https://www.businesswire.com/news/home/20200529005347/en/
    Technavio has announced its latest market research report titled Global Stent Grafts Market 2020-2024 (Graphic: Business Wire)
    Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19.
  • Market estimates include pre- and post-COVID-19 impact on the Stent Grafts Market.
  • Increasing prevalence of aortic aneurysms and co-morbidities has been instrumental in driving the growth of the market.

AngioSoma Focusing on Development of Coating for Metal Stents

Wednesday, May 27, 2020 - 3:42pm

Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.

Key Points: 
  • Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.
  • Our coating is a biodegradable, resorbable and hemocompatible surface substrate coating for metal stents to provide embolic protection in stenting procedures.
  • We believe our coating for stents has increased potential over and above what is on the market now to block restenosis (recurrence of narrowing).
  • We consider the addressable market for stents includes not only carotid artery stenting patients but also individuals undergoing carotid endarterectomy.

Merit Medical Receives CE Mark for Wrapsody™ Endovascular Stent Graft System

Tuesday, May 26, 2020 - 2:25pm

(NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY Endovascular Stent Graft System from the British Standards Institution (BSI).

Key Points: 
  • (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, today announced that it received the CE mark for the WRAPSODY Endovascular Stent Graft System from the British Standards Institution (BSI).
  • Merit recently completed enrollment and primary follow-up of its WRAPSODY FIRST study which included 46 patients in Europe.
  • Merit intends to systematically introduce the WRAPSODY system in Europe as procedures are resumed following the ongoing lockdown due to COVID-19.
  • The WRAPSODY system is complementary to other products that Merit produces or distributes, such as the HeRO Graft, the Surfacer Inside-Out Access Catheter System and other vascular access products.

Inivata Announces Strategic Collaboration and Investment from NeoGenomics

Tuesday, May 26, 2020 - 10:06am

Research Triangle Park, NC, USA and Cambridge, UK, 26 May 2020 -- Inivata, a leader in liquid biopsy, today announces the formation of a strategic collaboration with NeoGenomics, Inc (NASDAQ: NEO), for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States.

Key Points: 
  • Research Triangle Park, NC, USA and Cambridge, UK, 26 May 2020 -- Inivata, a leader in liquid biopsy, today announces the formation of a strategic collaboration with NeoGenomics, Inc (NASDAQ: NEO), for the commercialization of its InVisionFirst-Lung liquid biopsy test in the United States.
  • Inivata and NeoGenomics will also seek opportunities for collaboration with biopharmaceutical companies around Inivatas liquid biopsy platform, drawing on both companies technology and expertise.
  • As part of the collaboration, NeoGenomics will make a $25 million equity investment in Inivata to take a minority shareholding with an option to buy the company outright.
  • Clive Morris, CEO of Inivata, commented: This strategic collaboration and equity investment provides the platform to significantly accelerate the commercialization of InVisionFirst-Lung in the US, and bring its benefits more rapidly to patients and clinicians.

The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019. The market is projected to grow at a CAGR of 12.1% from 2020 to 2027

Saturday, May 23, 2020 - 1:15am

The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019.

Key Points: 
  • The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019.
  • The market is projected to grow at a CAGR of 12.1% from 2020 to 2027.
  • The radiofrequency ablation devices market growth is primarily attributed to the rising prevalence of chronic diseases, emerging applications of radiofrequency ablation technology, and increasing preference for minimally invasive procedures in Asia Pacific.
  • In 2019, the surgical oncology segment held the largest share of the Asia Pacific radiofrequency ablation devices market, by application, in 2019.

Centesis Catheters Market Worth $633 Million by 2025 - Exclusive Report by MarketsandMarkets™

Friday, May 22, 2020 - 1:30pm

Small-bore centesis catheters segment accounted for the largest share of the centesis catheters market, by type, in 2018

Key Points: 
  • Small-bore centesis catheters segment accounted for the largest share of the centesis catheters market, by type, in 2018
    Based on type, the centesis catheters market is segmented into small-bore and large-bore centesis catheters.
  • The small-bore centesis catheters segment accounted for the largest share of this market in 2018.
  • This can be attributed to the wide availability of small-bore centesis catheters, growing number of target procedures that require small-bore centesis catheters, increasing evidence of the efficacy and safety of small-bore centesis catheters over large-bore centesis catheters, and their higher adoption in diagnostic centesis procedures.
  • Paracentesis procedures segment accounted for the largest share of the centesis catheters market, by procedure, in 2018
    Based on procedure, the centesis catheters market is segmented into paracentesis, thoracentesis, arthrocentesis, amniocentesis, and other procedures.

Centesis Catheters Market Worth $633 Million by 2025 - Exclusive Report by MarketsandMarkets™

Friday, May 22, 2020 - 1:30pm

Small-bore centesis catheters segment accounted for the largest share of the centesis catheters market, by type, in 2018

Key Points: 
  • Small-bore centesis catheters segment accounted for the largest share of the centesis catheters market, by type, in 2018
    Based on type, the centesis catheters market is segmented into small-bore and large-bore centesis catheters.
  • The small-bore centesis catheters segment accounted for the largest share of this market in 2018.
  • This can be attributed to the wide availability of small-bore centesis catheters, growing number of target procedures that require small-bore centesis catheters, increasing evidence of the efficacy and safety of small-bore centesis catheters over large-bore centesis catheters, and their higher adoption in diagnostic centesis procedures.
  • Paracentesis procedures segment accounted for the largest share of the centesis catheters market, by procedure, in 2018
    Based on procedure, the centesis catheters market is segmented into paracentesis, thoracentesis, arthrocentesis, amniocentesis, and other procedures.

InventHelp Inventor Develops Nephrostomy Underwear (CEO-125)

Thursday, May 21, 2020 - 5:45pm

PITTSBURGH, May 21, 2020 /PRNewswire/ -- "My husband has nephrostomy tubes which are tedious to empty," said an inventor from Wadsworth, Ohio.

Key Points: 
  • PITTSBURGH, May 21, 2020 /PRNewswire/ -- "My husband has nephrostomy tubes which are tedious to empty," said an inventor from Wadsworth, Ohio.
  • "This inspired me to develop underwear which can make the wearer's life easier while allowing him to have a normal appearance."
  • She developed the EASY WEAR that allows nephrostomy pouches to be easily emptied to save wearers and caregivers time, energy and frustration.
  • This underwear could reduce the mess associated with emptying the pouch to reduce the amount of laundry.

Profound Medical Annual and Special Meeting of Shareholders Voting Results

Wednesday, May 20, 2020 - 9:30pm

Detailed voting results for all resolutions will be posted under the Companys profile at www.sedar.com .

Key Points: 
  • Detailed voting results for all resolutions will be posted under the Companys profile at www.sedar.com .
  • Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
  • Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control.
  • Profound is also commercializing SONALLEVE, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

AngioSoma's Development of Atherectomy Catheter

Wednesday, May 20, 2020 - 2:54pm

This device uses a camera that allows physicians to better control treatment of PAD patients.

Key Points: 
  • This device uses a camera that allows physicians to better control treatment of PAD patients.
  • We have not applied to the United States Food and Drug Administration for clearance to market the Atherectomy Catheter II as a treatment for severely calcified coronary arteries.
  • In addition, the Atherectomy Catheter II includes a vacuum mechanism that extracts any removed plaque from the arteries and from the patient.
  • According to estimates by the American Heart Association, as many as 8 to 12 million Americans have PAD.